Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.36 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10301615 | 0.92 | KDM1A (0.42) | KDM1APDE4A | |
| SCHEMBL15381494 | 0.91 | KDM1A (0.39) | KDM1ASCN9APDE4APDE4BPDE4C | |
| SCHEMBL10301613 | 0.91 | SLC6A2 (0.37) | KDM1ASPHK1CNR2CNR1PDE4A | |
| SCHEMBL18175644 | 0.91 | KDM1A (0.37) | KDM1ASPHK1CNR2CNR1SCN9A | |
| SCHEMBL15381590 | 0.90 | KDM1A (0.42) | KDM1APDE4A | |
| SCHEMBL15381796 | 0.89 | KDM1A (0.39) | KDM1ASCN9APDE4APDE4BPDE4C | |
| SCHEMBL18175659 | 0.88 | SCN9A (0.36) | KDM1ASPHK1CNR2CNR1SCN9A | |
| SCHEMBL12735831 | 0.88 | CYP2C9 (0.33) | KDM1ASPHK1CNR2CNR1SCN9A | |
| SCHEMBL18175648 | 0.87 | KDM1A (0.37) | KDM1ACNR2CNR1SCN9APDE4A | |
| SCHEMBL10301614 | 0.87 | KDM1A (0.44) | KDM1ATSHRPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | KDM1A 549/4885SPHK1 2309/4885CNR2 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.